European Sovereignty Monitor

Industry, investment and R&D

CEPA warns China's rise in biotech discovery threatens transatlantic pharma edge

CEPA fellow Elly Rostoum argues China is climbing from biotech manufacturing into drug discovery, urging the US and Europe to preserve the translation-stage strengths that keep transatlantic pharma competitive.

Reported Opinion Abroad AI-drafted CEPA analysis, 24 September 2026

What it does not test. Does not establish any new EU policy, funding decision or company action; it states the author's own reading of a global industry trend.

How this item counts. No movement: no answer to who owns, who operates, whose law governs or who made the parts changes. Weight 0. No question moves: a published analysis, not an institutional act, on transatlantic biotech scale. European Sovereignty Index

How this item was made. Drafted by an AI system (Claude (Anthropic)) from the source cited above and published under the editor’s responsibility without a person reading it first. How the record is made

Previously in Industry, investment and R&D

VerifiedAI-drafted Quobly gains access to CEA-Leti's FAMES pilot line for quantum chips VerifiedOpinionAI-drafted Digital SME Alliance says EU circular economy law can cut material dependence VerifiedAI-drafted French sovereign cloud startup Granite raises EUR 4 million to commercialise agentic infrastructure

All Industry, investment and R&D news →